<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00540657</url>
  </required_header>
  <id_info>
    <org_study_id>CL009_282</org_study_id>
    <nct_id>NCT00540657</nct_id>
  </id_info>
  <brief_title>A Phase II Study of CCX282-B in Patients With Celiac Disease</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ChemoCentryx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ChemoCentryx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether CCX282-B is effective in mitigating the
      effects of gluten ingestion in patients with celiac disease
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the effect of CCX282-B compared to placebo on the villous height/crypt depth ratio of small intestinal biopsy specimens taken from subjects with celiac disease, before and after gluten exposure.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of CCX282-B compared to placebo on small intestinal mucosal inflammation before and after gluten exposure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of CCX282-B compared to placebo on gluten-induced celiac-type serology before and after gluten exposure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of CCX282-B compared to placebo on symptom scores before and after gluten exposure</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Celiac Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCX282-B</intervention_name>
    <description>250mg capsule, twice daily, 13 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule, twice daily, 13 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female, between 18 and 75 years of age

          -  Established diagnosis of celiac disease

          -  Subject has been following a strict gluten-free diet for at least 24 months

        Key Exclusion Criteria:

          -  History of any infection requiring intravenous antibiotics, a serious local infection,
             systemic infection, or gastrointestinal infection within 12 weeks of randomization

          -  Use of any immunosuppressants, TNF inhibitors, or natalizumab during the 12 weeks
             prior to study randomization

          -  Use of steroids during the 4 weeks prior to study randomization

          -  Receipt of an experimental treatment for any disease within 4 weeks prior to
             randomization

          -  Known IgE-mediated atopy or allergy or anaphylactic reactions to gluten

          -  The subject suffers from a condition that carries a risk at endoscopy or is on
             anticoagulant treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markku MÃ¤ki, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tampere</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gordon Hamilton, MD</last_name>
    <role>Study Director</role>
    <affiliation>ChemoCentryx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Finn-Medi Research Ltd, Outpatient Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>FIN-33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2007</study_first_submitted>
  <study_first_submitted_qc>October 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2007</study_first_posted>
  <last_update_submitted>July 21, 2008</last_update_submitted>
  <last_update_submitted_qc>July 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Pirow Bekker</name_title>
    <organization>ChemoCentryx</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celiac Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

